HPB
Brittany C. Fields, MD, MPH (she/her/hers)
T32 Resident Research Fellow
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Brittany C. Fields, MD, MPH (she/her/hers)
T32 Resident Research Fellow
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Brittany C. Fields, MD, MPH (she/her/hers)
T32 Resident Research Fellow
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Tim Vreeland, MD
Clinical General Surgical Oncology Fellow
The University of Texas MD Anderson Cancer Center, United States
Tim Newhook, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Rebecca A. Snyder, MD, MPH (she/her/hers)
Associate Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Jess E. Maxwell, MD, MBA (she/her/hers)
Assistant Professor of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Laura R. Prakash, MD
Clinical Research Scientist
The University of Texas MD Anderson Cancer Center, United States
Michael P. Kim, MD
Associate Professor of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Naruhiko Ikoma, MD, MS
Assistant Professor of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Jeffrey E. Lee, MD
Vice President of Clinical Operations
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Matthew H.G Katz, MD (he/him/his)
Professor and Chair
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Ching-Wei D. Tzeng, MD (he/him/his)
Associate Professor of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
A prospective institutional database was reviewed for PDAC treated with NT followed by laparoscopy prior to or on the date of planned resection (Feb. 2009 – Mar. 2023). Those who underwent laparoscopy to biopsy radiographically suspicious lesions were excluded. Clinicopathologic data, treatment details, and CA 19-9 from pre-NT (CA-PRE), mid-therapy (CA-MID) and post-NT (CA-POST) were analyzed.